Citation
J Haem Pract 2014; 1(2):J Haem Pract 2014; 1(2): 24-29. doi: 10.17225/jhp00021

Authors: Christine Harrington, Charles RM Hay, Vicky Vidler, Rashesh Dattani, Katherine Heygate

Christine Harrington
Nurse Consultant (Haemophilia)
Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free Hospital, London NW3 2QG, UK.

Professor Charles RM Hay
Professor of Haemostasis and Thrombosis, Consultant Haematologist and Director
Manchester Haemophilia Comprehensive Care Centre, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK.

Vicky Vidler
Nurse Consultant (Paediatric Haematology)
Sheffield Children's Foundation NHS Trust, Western Bank, Sheffield S10 2TH, UK.

Rashesh Dattani
Clinical Nurse Specialist/Centre Manager
Haemostasis and Thrombosis Centre, Leicester Royal Infirmary, Infirmary Square, Leicester LE1 5WW, UK.

Katherine Heygate
Senior Medical Adviser
Novo Nordisk UK, City Place, Beehive Ring Rd, Crawley, Gatwick, West Sussex RH6 0PA, UK.

Abstract

Clotting factor concentrates used in the treatment of haemophilia are now procured centrally in the UK by nationally organised competitive tendering to obtain the best product price while still preserving some degree of prescribing freedom. Inevitably, however, some patients are required to switch from one brand of factor VIII to another to fulfil contractual requirements. This process of switching patients from one product to another falls to staff at individual haemophilia centres, with haemophilia nurses in particular playing a key role. This article outlines the national procurement process and discusses how the switch can be managed quickly and smoothly, as well as providing practical guidance on selecting which patients may be asked to switch. Issues such as patient communication, managing potential patient anxiety and efficient stock management are also discussed.

Acknowledgements

This paper is based on a roundtable discussion meeting funded by Novo Nordisk. The authors wish to thank: Jemma Efford, Clinical Nurse Specialist, Great Ormond Street Hospital, London; Emma Franklin, Haemophilia Clinical Nurse Specialist, Bristol Haemophilia Comprehensive Care Centre; Lisa Grainger, Advanced Nurse Practitioner, Oxford Haemophilia & Thrombosis Centre, Churchill Hospital, Oxford; Kingsley Lawrence, Specialist Haemophilia Nurse, Cambridge Haemophilia Centre, Addenbrooke's Hospital, Cambridge; Barbara Subel, Clinical Nurse Specialist, Haemophilia, Katharine Dormandy Haemophilia Centre & Thrombosis Unit, Royal Free Hospital, London; Julie Vowles, Nurse Specialist, Haemophilia Centre, Royal Victoria Infirmary, Newcastle Upon Tyne.
Editorial support for production of this paper was provided by Jane Smalls, Meritus Communications, Kent and funded by Novo Nordisk.

References

  1. Hay CRM. Purchasing factor concentrates in the 21st century through competitive tendering. Haemophilia 2013; 19(5):660-7.
  2. Sharrer I, Ehrlich HJ. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII. Haemophilia 2001; 7: 766.
  3. Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following widespread introduction of recombinant factor VIII replacement therapy. Transfusion Science 1998; 19(2): 139–148.
  4. Rubinger M, Lillicrap D, Rivard GE, et al. A prospective surveillance study of factor VIII inhibitor development in the Canadian hemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia 2008; 14(2): 281–286.
  5. Collins P, Chalmers E, Hart DP et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organisation. Haematol 2013; 160: 153–170.
  6. Hay CR, Palmer B, Chalmers E, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367-6370.
  7. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453–459.
  8. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. ReFacto Phase 3 Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38–49.
  9. Rothschild C, Laurian Y, Satre EP et al. French previously untreated patients with severe haemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thrombosis and Haemostasis 1998; 80: 779 –783.
  10. Gouw SC, van den Berg HM, le Cessie S et al. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. Journal of Thrombosis and Haemostasis 2007; 5: 1383-1390.
  11. Franchini M, Makris M, Santagostino E, et al. Non-thrombotic-, non-inhibitorassociated adverse reaction to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand’s disease: a systematic review of prospective studies. Haemophilia 2012; 18(3): e164–72.
  12. Gouw SC, van der Bom JG, Ljung R et al for the PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe haemophilia A. N Engl J Med 2013; 368: 231–9.

The Journal of Haemophilia Practice is published by Haemnet.

Haemnet is a registered charity that brings together and gives a voice to haemophilia nurses, physiotherapists and allied health care professionals, providing forums for collaborative research, educational activities and support.